Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Male Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

NCT01646060
View directory record Official record
Conditions
Blood Loss, Healthy
Interventions
CM-1500
Device
Lead sponsor
Zynex Monitoring Solutions
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 PK/PD Study

NCT02608710
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

NCT02641899
View directory record Official record
Conditions
Healthy
Interventions
ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

NCT06088264
View directory record Official record
Conditions
Healthy Male Participants
Interventions
BMS-986322
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Kidney Problems

NCT05992155
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 10, 2026, 5:43 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

NCT06782659
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001, Viagra, ASP-001
Drug · Device
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
View directory record Official record
Conditions
Healthy Subjects
Interventions
Tavapadon tablet, Tavapadon [14C] suspension
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

NCT00648076
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

NCT01605461
View directory record Official record
Conditions
Healthy
Interventions
BI 207127 NA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Tablet Relative Bioavailability

NCT01986556
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg (Site 1), Lesinurad 400 mg (Site 2, Lot A), Lesinurad 400 mg (Site 2, Lot B)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

NCT01199523
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, mirabegron, moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

NCT02194491
View directory record Official record
Conditions
Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
Interventions
[11C]AS2471907, Positron Emission Tomography (PET), ASP3662
Other · Radiation · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 10, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

NCT06872866
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001.1, ASP-001.1
Drug · Device
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
20 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

NCT00549653
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 10, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 10, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males

NCT00540553
View directory record Official record
Conditions
Healthy Subjects, Androgen Deficiency
Interventions
placebo, GSK971086
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 10, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

NCT00785551
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
quinine sulfate
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

NCT00427596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 10, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

NCT06799013
View directory record Official record
Conditions
Vaccine, Crimean-Congo Hemorrhagic Fever
Interventions
10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
Biological
Lead sponsor
HDT Bio
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 10, 2026, 5:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
40
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 10, 2026, 5:43 PM EDT